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Introduction. Pregnancy-related cancer is defined as cancer diagnosed during pregnancy or in the first postpartum 
year. Cervical cancer affects approximately 1 in 1000 pregnant women and is the most common malignancy affecting 
pregnancy. We retrospectively analysed the clinical outcome and results of treatment in patients with pregnancy-
-related cervical cancer.
Material and methods. We retrospectively analysed the medical records of nine patients with invasive cervical 
cancer diagnosed during pregnancy and the postpartum period who had been treated in the Regional Oncological 
Centre, Łódź, between 2011–2014. 
Results. Three patients with cervical cancer at stage I were diagnosed between the 14th and 17th week of pregnancy 
afterwards and underwent radical surgery. Two patients with cervical cancer at stage Ib who were diagnosed in the 
19th and 24th week of gestation decided to continue pregnancy until the 30th and 32nd week; then a cesarean section 
combined with radical surgery was performed. In three patients with inoperative cervical cancer diagnosed between 
the 26th and 28th week of pregnancy, a cesarean section was performed at week 30–32. In one patient cervical can-
cer at stage IIb was diagnosed during the post-partum period. All patients were treated using intensity-modulated 
radiotherapy (IMRT) to a total dose of 44 Gy/2Gy, weekly cisplatin (40 mg/m2) concurrent with radiotherapy and 
brachytherapy. No toxicity was observed. During follow-up, two patients with inoperable cervical cancer were diag-
nosed with a recurrence 2 and 10 months after treatment, respectively.
Conclusions. The management of pregnancy-related cervical cancer is mainly determined by the week of the preg-
nancy and the stage of the disease at diagnosis, but also by the patient choice. The general condition and follow-up 
of newborns from pregnancies complicated by cervical cancer are similar to those of newborns arising from non-
-complicated pregnancies. Treatment toxicity is similar in cases with pregnancy-related cervical cancer and in non-
-pregnant women with cervical cancer. The major prognostic factor in pregnancy-related cervical cancer remains 
the stage of the disease at diagnosis.
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Introduction 
Pregnancy-related cancer is defined as cancer diagnosed 
during pregnancy or in the first postpartum year [1–3]. 
With regards to changes of lifestyle of women in recent 
years and the conscious decision to delay procreation, the 
frequency of malignant tumours occurring simultaneously 
with pregnancy is growing. The most frequently diagnosed 
cancers among pregnant and post-partum women are: 
cervical cancer, breast cancer, melanoma, lymphoma and, 
to a lesser degree, leukaemia [4–6]. 
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The incidence of cervical cancer ranks second after 
breast cancer in the world population of women with peak 
mortality in the peri-menopausal period. However, in Po-
land, about 1/3 of all cases of this cancer are diagnosed in 
women in the procreative age. As the data of the National 
Cancer Register shows, in Poland the prevalence of cervical 
cancer has been decreasing since the mid-1980s, with 2909 
new cases and 1669 deaths from malignant tumours in this 
location, registered in 2013 [7]. Almost 3% of cases of cervi-
cal cancer occur during pregnancy and in the post-partum 
period and the frequency of diagnosing cervical cancer in 
pregnancy is 1:1000 pregnancies [8–12]. The average age 
of women with cervical cancer diagnosed in pregnancy is 
31 years. It is believed that thanks to frequent obstetrical 
examinations during pregnancy, the possibility of diagnos-
ing cervical cancer in pregnant women is three times greater 
than in the case of non-pregnant women [13]. 
The objective of this study was to perform clinical analy-
sis and the evaluation of treatment results in patients with 
pregnancy-related cervical cancer, treated in the Regional 
Oncological Centre, Łódź, in 2011–2014. 
Materials and methods 
The medical files of patients treated at the Department 
of Tele-radiotherapy of N. Copernicus Voivodeship Specialist 
Hospital in Łódź, treated in 2011–2014 were analysed. There 
were 9 patients with histopathologically confirmed cervical 
cancer diagnosed during pregnancy or the post-partum 
period. The advancement stage of the cancers was evaluated 
according to FIGO classification (International Federation of 
Gynaecology and Obstetrics). The treatment of all patients 
consisted of tele-radiotherapy in connection with cisplatin 
(radio-chemotherapy) and brachytherapy. 
The patients received conformal IMRT tele-radiotherapy 
up to 44 Gy in 22 fractions of 2 Gy (5 fractions per week with 
a two-day break) in connection with cisplatin injections with 
a dose of 40 mg/m2 once per week with adjuvant treatment 
(Figs. 1, 2). The process of planning conformal radiotherapy 
consisted of rendering planar computed tomography im-
ages and planning the dose distribution in target volumes 
with the three-dimensional technique. The clinical target 
volume (CTV), in the case of post-surgery patients com-
prised the tumour bed left after the excised reproductive 
organ as well as regional lymph nodes: common iliac, ex-
ternal and internal, obturator and presacral lymph nodes. 
In non-surgical cases, the CTV area comprised the tumour-
-infiltrated uterine cervix and body, vaginal walls and fornix, 
parametria and regional lymph nodes. 
Tele-radiotherapy was combined with high dose radio-
therapy (HDR), with the system after loading, consisting in 
the remote implantation of radioactive substances on the 
guides located in the reproductive organ. The irradiation 
source was iridium 192. Intracavitary applications were per-
formed with the use of intravaginal applicators and uterine 
probes. The diameter of cylindrical applicators was adapted 
to the anatomic conditions (cylinders with the diameter 
of 2.5–4.0 cm). Brachytherapy planning and applicators 
placement verification was made with the assistance of 
computed tomography paired with the computed system 
of calculating the distribution of irradiation dosage. 
The clinical parameters, the course of treatment and 
its results were analysed. In the study group, the analysed 
Figure 1. Radiotherapy planning in patient with non-resectable cervical cancer — IMPR technique
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parameters were the age of the patients, the course of preg-
nancy, type of delivery and obstetric results as well as the 
tolerance and the results of the oncological treatment. The 
intensity of irradiation reactions was evaluated with the 
RTOG/EORTC scale (Radiation Therapy Oncology Group/Eu-
ropean Organization for Research and Treatment of Cancer).
Results 
Cervical cancer was diagnosed in eight pregnant pa-
tients in the 2nd and 3rd trimester of gestation, and in one 
case — during the post-partum period. The clinical char-
acteristics of the study group is presented in Table I. The 
treatment protocols were varied depending on the clinical 
situation of the patient. Before the commencement of the 
treatment, all the patients were informed in detail about 
their clinical situation and gave their consent for the pro-
posed method of treatment.
In five cases, cervical cancer was diagnosed in the sec-
ond trimester of gestation — in gestation week 14, 14, 17, 
19 and 24 respectively. In three patients, cervical cancer 
was diagnosed in its second stage of clinical advancement, 
between the 14th and 17th gestation week, and Wertheim-
-Meigs surgery was performed. Two other patients with 
cervical cancer, stage: IB, diagnosed in gestation week 19 
and 24 (2nd trimester), continued pregnancy till gestation 
week 30 and 32. During that period they received no on-
cological treatment. After the assessment of lung maturity 
in the foetuses, the patients underwent caesarean section 
together with Wertheim-Meigs surgery (Figs. 3, 4). In three 
other patients, cervical cancer was diagnosed in the third 
trimester, between gestation week 26 and 28. These gesta-
tions were continued with no oncological treatment till 
week 30–32 and then a caesarean section was performed 
after the previous assessment of the foetal lung maturity. 
In three cases, the cancer development stage (IIB, IIIA, IIIB) 
made radical surgery impossible. In one patient who gave 
birth to a healthy child, cervical cancer was diagnosed in the 
post-partum period. All the five infants born by caesarean 
section, between gestation week 30 and 32, survived. There 
were no adaptation complications observed in the infants 
born from the pregnancies with cervical cancer in the moth-
ers. The infants, after the end of the adaptation period, were 
discharged from the neonatology ward in good shape.
The treatment in the surgical ward was carried out ac-
cording to the above described protocol. No significant 
complications were observed in the course of the treatment. 
After treatment completion, the patients went through 
a follow-up in an outpatient unit of the oncology centre. 
The specific data concerning the follow-up period in spe-
cific cases is presented in Table 1. In two patients, cancer 
recurrence was diagnosed 2 and 10 months after treatment 
completion. The patient, in whom distant metastases were 
diagnosed in the lungs and liver, died within 8 weeks of 
the diagnosis of the primary cervical cancer. In the second 
Figure 2. Radiotherapy planning in patient with non-resectable cervical cancer — VMAT Volumetric Modulated Arc Therapy) technique
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patient, palliative treatment was applied. Currently, her neo-
plastic process has been stabilised. 
During the radiotherapy, the intensification of an early 
post-irradiation reaction was evaluated in the RTOG scale 
every 7 days. During the oncological treatment, in two pa-
tients, some post-irradiation grade I and II reactions were 
found in the area of the anus and the urinary bladder. No 
grade III or IV reactions were found. 
Figure 3. Pelvic lymphadenectomy during radical surgery for cervical cancer
Figure 4. Exophytic cervical cancer — post-surgical specimen
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Discussion
The publications present contradictory opinions con-
cerning the effect of pregnancy on the biology of cervi-
cal cancer. Some potential factors modifying the course 
of oncological disease in pregnant patients are increased 
perfusion and lymphatic drainage of the organs, hormonal 
factors and immunomodulation. In the opinion of some 
investigators, immunosuppression during pregnancy might 
foster the dissemination of cancer, whist other authors in 
turn, believe that pregnancy does not affect the course of 
cancer in any significant way [14]. There is no convincing 
evidence concerning the course of cervical cancer in preg-
nancy, so it seems highly necessary to continue research in 
this respect [15–17].
The cancer development stage and the period of preg-
nancy are of key significance for the choice of optimal thera-
peutic treatment [18]. The core examination necessary for 
the evaluation of the local development stage of the cancer 
in a precise way is nuclear magnetic resonance imaging 
(NMR) (Fig. 5) [19]. A detailed evaluation of the lymphatic 
system of the abdomen paired with a clinical assessment of 
the patient and an NMR examination allows one to establish 
the optimal pattern of treatment. In pregnant patients, CT is 
not performed unless there are life-threatening issues [20].
Another factor affecting the choice of the treatment 
strategy is the period of gestation in which the cervical 
cancer is diagnosed [21]. If the diagnosis is made in the first 
two trimesters of gestation, the continuation of pregnancy 
for many weeks would lead to a significant delay in the 
commencement of treatment, worsening the prognosis; 
therefore it is recommended to terminate the pregnancy 
and commence treatment urgently. Given the immense 
progress of perinatology, if cervical cancer is diagnosed at 
the end of the second trimester of gestation (week 23–24), 
the therapeutic decisions must be individualised and based 
on the evaluation of the clinical situation and the possibili-
ties of the institution [22]. In the study group, in the cases 
when cervical cancer was diagnosed in the second trimester, 
it was decided to terminate the pregnancy and to begin 
oncological treatment as fast as possible. If the cancer is 
diagnosed in the third trimester of pregnancy, the gesta-
tion is most frequently continued till the moment when 
Figure 5. Cervical cancer in a pregnant women in 3rd trimester — NMR imaging
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the foetal maturity allows for the delivery of an infant who 
is cardiovasculary and respiratorily stable. Then, similarly to 
the study group, a caesarean section is performed and onco-
logical treatment begins. In the two-above cases of resect-
able cervical cancers, the caesarean section was combined 
with radical surgery which is compliant with the binding 
treatment standards.
The core of radiotherapy of cervical cancer diagnosed in 
pregnancy lies in the adequate and precise combination of 
tele-radiotherapy with the injections of platinum compounds 
and with brachytherapy. According to the recommendations 
of the American Brachytherapy Society, the total duration of 
radiotherapy should not exceed 8 weeks [23]. The sequence 
of application and the size of fractional and therapeutic doses 
are still disputable and in practice they are individually estab-
lished. With regards to the manner of fractionation of HDR 
brachytherapy (1 × week), it is really essential to observe the 
appropriate duration of tele-radiotherapy. The publications 
on this issue, emphasise the adverse effect of prolonged ra-
diotherapy on prognoses in patients with cervical cancer [24]. 
As the diagnosis of cervical cancer in pregnancy prolongs the 
time period till the commencement of radiotherapy, which is 
prognostically adverse, in advanced stages of cervical cancer, 
the radio-chemotherapy should be commenced immediately 
after childbirth.
In pregnant women with cervical cancer, the prognoses 
are similar to patients who are not pregnant. The cancer 
stage at the moment of diagnosis is regarded as the core 
factor which determines the prognosis, which was also 
confirmed in this study [18, 25–30]. In the study group, 
cancer recurrence was found in two cases in which cervical 
cancer was diagnosed in the locally advanced stage of the 
disease. No recurrence was observed among other patients 
with resectable surgical cancer. In addition, no relationship 
was found between the age of the patients and the progno-
ses. The small number of subjects within the study group, 
however, does not allow for a generalisation of the results 
onto the population. With respect to many controversies 
and doubts connected with the issue of cervical cancer 
in pregnancy, it is necessary to carry out further research 
to ensure we gain better knowledge of the biological and 
pathophysiological mechanisms of this cancer. 
Conclusions
1. The advancement stage of cervical cancer, the period of 
pregnancy in which the cancer was diagnosed as well as 
the attitude of the patient being aware of her situation 
determine the course of action in this group of patients.
2. The general condition and the course of the adapta-
tion period of the infants born from the pregnancies 
complicated with cervical cancer do not differ from 
the condition of infants born by healthy mothers in the 
equivalent gestation weeks.
3. The tolerance of radiotherapy and radio-chemotherapy 
in post-partum women with cervical cancer diagnosed 
in pregnancy does not differ from the tolerance of this 
type of treatment in non-pregnant women with cervi-
cal cancer.
4. The core factor which determines the prognoses for 
patients with cervical cancer remains the cancer ad-
vancement stage at the moment of diagnosis. 
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